share_log

In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals

Benzinga ·  Sep 17 20:01

ANI Pharmaceuticals (NASDAQ:ANIP) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings30100
Last 30D10000
1M Ago00100
2M Ago10000
3M Ago10000

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $85.5, a high estimate of $94.00, and a low estimate of $60.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.66%.

1726574513_0.png

Interpreting Analyst Ratings: A Closer Look

The perception of ANI Pharmaceuticals by financial experts...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment